|
1
|
One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.
|
Diabetes
|
2004
|
2.74
|
|
2
|
Glucagon-like peptide-1: regulation of insulin secretion and therapeutic potential.
|
Basic Clin Pharmacol Toxicol
|
2004
|
1.73
|
|
3
|
Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions.
|
Diabetes Care
|
2007
|
1.57
|
|
4
|
Amylin agonists: a novel approach in the treatment of diabetes.
|
Diabetes
|
2004
|
1.49
|
|
5
|
[Postprandial hyperglycemia. Postprandial blood glucose fluctuations, cardiovascular disease and late diabetic complications].
|
Ugeskr Laeger
|
2003
|
1.39
|
|
6
|
[The place of Glitazones in the treatment of diabetes: after the PROactive study].
|
Ugeskr Laeger
|
2006
|
1.38
|
|
7
|
Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia.
|
Diabetes
|
2004
|
1.37
|
|
8
|
The effect of systematic medication review in elderly patients admitted to an acute ward of internal medicine.
|
Basic Clin Pharmacol Toxicol
|
2010
|
0.99
|
|
9
|
SLC30A3 responds to glucose- and zinc variations in beta-cells and is critical for insulin production and in vivo glucose-metabolism during beta-cell stress.
|
PLoS One
|
2009
|
0.99
|
|
10
|
Zinc-transporter genes in human visceral and subcutaneous adipocytes: lean versus obese.
|
Mol Cell Endocrinol
|
2006
|
0.96
|
|
11
|
Identifying high-risk medication: a systematic literature review.
|
Eur J Clin Pharmacol
|
2014
|
0.96
|
|
12
|
Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer´s disease - protocol for a controlled, randomized double-blinded trial.
|
Dan Med J
|
2012
|
0.89
|
|
13
|
Glucagon-like peptide-1 inhibits blood-brain glucose transfer in humans.
|
Diabetes
|
2007
|
0.88
|
|
14
|
Glucagon-like peptide-1 decreases intracerebral glucose content by activating hexokinase and changing glucose clearance during hyperglycemia.
|
J Cereb Blood Flow Metab
|
2012
|
0.88
|
|
15
|
Diabetic autonomic neuropathy affects symptom generation and brain-gut axis.
|
Diabetes Care
|
2013
|
0.87
|
|
16
|
Differences between long-acting insulins for the treatment of type 2 diabetes.
|
Expert Opin Pharmacother
|
2010
|
0.87
|
|
17
|
At the centennial of Michaelis and Menten, competing Michaelis-Menten steps explain effect of GLP-1 on blood-brain transfer and metabolism of glucose.
|
Basic Clin Pharmacol Toxicol
|
2014
|
0.86
|
|
18
|
Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes.
|
Expert Opin Ther Targets
|
2011
|
0.84
|
|
19
|
No increased risk of hypoglycaemic episodes during 48 h of subcutaneous glucagon-like-peptide-1 administration in fasting healthy subjects.
|
Clin Endocrinol (Oxf)
|
2008
|
0.83
|
|
20
|
Glucagon-like peptide-1 (GLP-1) raises blood-brain glucose transfer capacity and hexokinase activity in human brain.
|
Front Neuroenergetics
|
2013
|
0.83
|
|
21
|
Medication Review and Patient Outcomes in an Orthopedic Department: A Randomized Controlled Study.
|
J Patient Saf
|
2015
|
0.79
|
|
22
|
Impact of glucagon-like peptide-1 on myocardial glucose metabolism revisited.
|
Rev Endocr Metab Disord
|
2014
|
0.78
|
|
23
|
New strategies in insulin treatment: analogues and noninvasive routes of administration.
|
Fundam Clin Pharmacol
|
2005
|
0.76
|
|
24
|
[Treatment of community-acquired pneumonia--treatment].
|
Ugeskr Laeger
|
2008
|
0.75
|
|
25
|
[Vaginal oestrogen therapy in women with hormone-sensitive breast cancer].
|
Ugeskr Laeger
|
2011
|
0.75
|
|
26
|
[Drug committees towards the regions. The Danish Society of Clinical Pharmacology].
|
Ugeskr Laeger
|
2007
|
0.75
|
|
27
|
Impact of dietary FA and energy restriction on plasma leptin and ob gene expression in mice.
|
Lipids
|
2003
|
0.75
|
|
28
|
Classification of drugs with different risk profiles.
|
Dan Med J
|
2015
|
0.75
|